- Home
- SENEA vs OMER Comparison
SENEA vs OMER Comparison
Compare SENEA & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- OMER
- Stock Information
- Founded
- SENEA 1949
- OMER 1994
- Country
- SENEA United States
- OMER United States
- Employees
- SENEA N/A
- OMER N/A
- Industry
- SENEA Packaged Foods
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- OMER Health Care
- Exchange
- SENEA Nasdaq
- OMER Nasdaq
- Market Cap
- SENEA 710.1M
- OMER 628.9M
- IPO Year
- SENEA N/A
- OMER 2009
- Fundamental
- Price
- SENEA $128.23
- OMER $9.41
- Analyst Decision
- SENEA
- OMER Strong Buy
- Analyst Count
- SENEA 0
- OMER 5
- Target Price
- SENEA N/A
- OMER $27.50
- AVG Volume (30 Days)
- SENEA 92.8K
- OMER 1.7M
- Earning Date
- SENEA 11-05-2025
- OMER 11-13-2025
- Dividend Yield
- SENEA N/A
- OMER N/A
- EPS Growth
- SENEA 47.79
- OMER N/A
- EPS
- SENEA 8.61
- OMER N/A
- Revenue
- SENEA $1,606,175,000.00
- OMER N/A
- Revenue This Year
- SENEA N/A
- OMER N/A
- Revenue Next Year
- SENEA N/A
- OMER N/A
- P/E Ratio
- SENEA $14.48
- OMER N/A
- Revenue Growth
- SENEA 8.33
- OMER N/A
- 52 Week Low
- SENEA $70.20
- OMER $2.95
- 52 Week High
- SENEA $129.04
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- SENEA 66.50
- OMER 64.25
- Support Level
- SENEA $119.37
- OMER $8.04
- Resistance Level
- SENEA $126.40
- OMER $10.00
- Average True Range (ATR)
- SENEA 5.18
- OMER 0.68
- MACD
- SENEA 1.18
- OMER 0.17
- Stochastic Oscillator
- SENEA 93.11
- OMER 83.78
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.